You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Introducing Anoro Ellipta

Anoro Ellipta (55 micrograms/22 micrograms inhalation powder) is a long acting muscarinic antagonist/long acting Beta2-adrenergic agonists (LAMA/LABA) and is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).1

Lungs

Only Anoro Ellipta

Demonstrated 1.4x statistically superior lung function improvement vs. TIO/OLO (180mL vs. 128mL change from baseline in trough FEV1 at week 8; 95% CI 28, 77; p<0.001)****2

Discover more >

2x Icon

Prescribe Anoro
Ellipta­­­1

To give your COPD patients 2x the odds of achieving a clinically meaningful improvement in lung function vs. tiotropium olodaterol2

Read more >

Knowledge Base

Watch webinars and videos, featuring experts in the respiratory field.

Find out more

 

References:

  1. Anoro Ellipta 52/22 mcg SPC.
  2. Feldman G.J et al. Adv Ther 2017; 34:doi 10.1007/s12325-017-0626-4.

ANORO Ellipta was developed in collaboration with INNOVIVA Inc.

Innoviva logo

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trademarks are owned by or licensed to the GSK group of companies